Background: Diisocyanate is widely used as a polymerizing agent for manufacturing many products. However, repeated inhalation exposure to diisocyanates in the workplace can cause bronchial asthma, hypersensitivity pneumonitis (HP), and neoplasia. Objectives: In the current study, immunological tests were conducted to explore the mechanisms involved in the pathogenesis of diisocyanate-induced HP. Methods: Evaluations included 4 patients with diisocyanate-induced HP, 4 volunteers with current occupational exposure to diisocyanates and 4 normal volunteers without a history of exposure to diisocyanates. IgG and IgA antibody levels to diisocyanates were determined by ELISA in sera and BAL fluids. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence or in the absence of 10 µg/ml MDI-HSA (4, 4′ diphenylmethane diisocyanate)-HSA (human serum albumin). 3H-thymidine uptake, mRNA expression by RT-PCR (beta-actin, IL-1beta, IL-2R, IL-4, IL-5, IL-6, IL-10, IFN-gamma, TNF-alpha, TGF-beta) were estimated. Results: Patients with diisocyanate-induced HP had detectable IgG and IgA antibodies to diisocyanates. In addition, PBMCs from HP patients proliferated in the presence of diisocyanates and showed enhanced expression of mRNA of proinflammatory cytokines. In contrast, normal volunteers with current occupational exposure showed elevated levels of mRNA expression of IL-10 and IL-2R, suggesting the presence of sensitized cells and protection from pathology as a result of enhanced IL-10 production. Conclusions: Patients with diisocyanate-induced HP are likely to override the protective effects of IL-10 as they express lower levels of this cytokine.

Keywords:
Diisocyanates, Isocyanates, Extrinsic allergic alveolitis, Hypersensitivity pneumonitis, IL-10, IL-2R
1.
Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM: Occupational asthma and extrinsic alveolitis due to isocyanates: Current status and perspectives. Br J Ind Med 1993;50:213–228.
2.
Vandenplas O, Malo JL, Dugas M, Cartier A, Desjardins A, Levesque J, Shaughnessy MA, Grammer LC: Hypersensitivity pneumonitis-like reaction among workers exposed to diphenylmethane [correction to diphenylmethane] diisocyanate (MDI). Am Rev Res Dis 1993;147:338–346.
3.
Raulf-Heimsoth M, Baur X: Pathomechanisms and pathophysiology of isocyanate-induced diseases – Summary of present knowledge. Am J Ind Med 1998;34:137–143.
4.
Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG: Inflammatory and immune processes in the human lung in health and disease: Evaluation by bronchoalveolar lavage. Am J Pathol 1979;97:149–206.
5.
Karol MH, Hauth BA, Alarie Y: Pulmonary hypersensitivity to hexyl isocyanate-ovalbumin aerosol in guinea pigs. Toxicol Appl Pharmacol 1979;51:73–80.
6.
Yoshizawa Y, Ohtsuka M, Noguchi K, Uchida Y, Suko M, Hasegawa S: Hypersensitivity pneumonitis induced by toluene diisocyanate: Sequelae of continuous exposure [see comments]. Ann Intern Med 1989;110:31–34.
7.
Baur X: Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocyanates. J Allergy Clin Immunol 1995;95:1004–1010.
8.
Grammer LC, Harris KE, Malo JL, Cartier A, Patterson R: The use of an immunoassay index for antibodies against isocyanate human protein conjugates and application to human isocyanate disease. J Allergy Clin Immunol 1990;86:94–98.
9.
Baur X: Immunologic cross-reactivity between different albumin-bound isocyanates. J Allergy Clin Immunol 1983;71:197–205.
10.
Schuyler M, Gott K, Fei R, Edwards B: Experimental hypersensitivity pneumonitis: Location of transferring cells. Lung 1998;176:213–225.
11.
Schuyler M, Gott K, Shopp G, Crooks L: CD3+ and CD4+ cells adoptively transfer experimental hypersensitivity pneumonitis. Am Rev Respir Dis 1992Dec;146:1582–1588.
12.
Gudmundsson G, Bosch A, Davidson BL, Berg DJ, Hunninghake GW: Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am J Respir Cell Mol Biol 1998;19:812–818.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.